Datasets:

nzindoc

/

dataset_pfs_by_arm

like 0

Can you inform me about the median PFS rate in patients that were treated with Lenalidomide+Dexamethasone+Elotuzumab (ERd) regimen?

Patients treated with the Lenalidomide+Dexamethasone+Elotuzumab (ERd) have a median Progression-Free Survival (PFS) rate of 19.4 months, with a 95% CI of (16.6, 22.2).

### Instruction: Can you inform me about the median PFS rate in patients that were treated with Lenalidomide+Dexamethasone+Elotuzumab (ERd) regimen? ### Response: Patients treated with the Lenalidomide+Dexamethasone+Elotuzumab (ERd) have a median Progression-Free Survival (PFS) rate of 19.4 months, with a 95% CI of (16.6, 22.2).

What is the median PFS rate for patients that have undergone Lenalidomide+Dexamethasone+Elotuzumab (ERd) regimen?

Patients treated with the Lenalidomide+Dexamethasone+Elotuzumab (ERd) have a median Progression-Free Survival (PFS) rate of 19.4 months, with a 95% CI of (16.6, 22.2).

### Instruction: What is the median PFS rate for patients that have undergone Lenalidomide+Dexamethasone+Elotuzumab (ERd) regimen? ### Response: Patients treated with the Lenalidomide+Dexamethasone+Elotuzumab (ERd) have a median Progression-Free Survival (PFS) rate of 19.4 months, with a 95% CI of (16.6, 22.2).

Could you tell me the median Progression-Free Survival rate for patients who received Lenalidomide+Dexamethasone+Elotuzumab (ERd) regimen?

Patients treated with the Lenalidomide+Dexamethasone+Elotuzumab (ERd) have a median Progression-Free Survival (PFS) rate of 19.4 months, with a 95% CI of (16.6, 22.2).

### Instruction: Could you tell me the median Progression-Free Survival rate for patients who received Lenalidomide+Dexamethasone+Elotuzumab (ERd) regimen? ### Response: Patients treated with the Lenalidomide+Dexamethasone+Elotuzumab (ERd) have a median Progression-Free Survival (PFS) rate of 19.4 months, with a 95% CI of (16.6, 22.2).

What’s the median rate of PFS in patients treated with Lenalidomide+Dexamethasone+Elotuzumab (ERd) regimen?

Patients treated with the Lenalidomide+Dexamethasone+Elotuzumab (ERd) have a median Progression-Free Survival (PFS) rate of 19.4 months, with a 95% CI of (16.6, 22.2).

### Instruction: What’s the median rate of PFS in patients treated with Lenalidomide+Dexamethasone+Elotuzumab (ERd) regimen? ### Response: Patients treated with the Lenalidomide+Dexamethasone+Elotuzumab (ERd) have a median Progression-Free Survival (PFS) rate of 19.4 months, with a 95% CI of (16.6, 22.2).

Can you share the median Progression-Free Survival rate in patients who have received Lenalidomide+Dexamethasone+Elotuzumab (ERd) regimen?

Patients treated with the Lenalidomide+Dexamethasone+Elotuzumab (ERd) have a median Progression-Free Survival (PFS) rate of 19.4 months, with a 95% CI of (16.6, 22.2).

### Instruction: Can you share the median Progression-Free Survival rate in patients who have received Lenalidomide+Dexamethasone+Elotuzumab (ERd) regimen? ### Response: Patients treated with the Lenalidomide+Dexamethasone+Elotuzumab (ERd) have a median Progression-Free Survival (PFS) rate of 19.4 months, with a 95% CI of (16.6, 22.2).

Can you tell me the median PFS for Lenalidomide+Dexamethasone (Rd)?

Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 14.9 months, with a 95% CI of (12.1, 17.2).

### Instruction: Can you tell me the median PFS for Lenalidomide+Dexamethasone (Rd)? ### Response: Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 14.9 months, with a 95% CI of (12.1, 17.2).

What’s the median PFS associated with Lenalidomide+Dexamethasone (Rd)?

Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 14.9 months, with a 95% CI of (12.1, 17.2).

### Instruction: What’s the median PFS associated with Lenalidomide+Dexamethasone (Rd)? ### Response: Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 14.9 months, with a 95% CI of (12.1, 17.2).

Could you provide the median PFS of Lenalidomide+Dexamethasone (Rd)?

Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 14.9 months, with a 95% CI of (12.1, 17.2).

### Instruction: Could you provide the median PFS of Lenalidomide+Dexamethasone (Rd)? ### Response: Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 14.9 months, with a 95% CI of (12.1, 17.2).

I’d like to know the median PFS of Lenalidomide+Dexamethasone (Rd).

Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 14.9 months, with a 95% CI of (12.1, 17.2).

### Instruction: I’d like to know the median PFS of Lenalidomide+Dexamethasone (Rd). ### Response: Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 14.9 months, with a 95% CI of (12.1, 17.2).

Do you have information on the median PFS of Lenalidomide+Dexamethasone (Rd)?

Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 14.9 months, with a 95% CI of (12.1, 17.2).

### Instruction: Do you have information on the median PFS of Lenalidomide+Dexamethasone (Rd)? ### Response: Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 14.9 months, with a 95% CI of (12.1, 17.2).

What is the median progression-free survival (PFS) for Lenalidomide+Dexamethasone (Rd)?

Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 14.9 months, with a 95% CI of (12.1, 17.2).

### Instruction: What is the median progression-free survival (PFS) for Lenalidomide+Dexamethasone (Rd)? ### Response: Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 14.9 months, with a 95% CI of (12.1, 17.2).

Can you inform me about the median PFS for Lenalidomide+Dexamethasone (Rd)?

Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 14.9 months, with a 95% CI of (12.1, 17.2).

### Instruction: Can you inform me about the median PFS for Lenalidomide+Dexamethasone (Rd)? ### Response: Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 14.9 months, with a 95% CI of (12.1, 17.2).

I’m interested in the median PFS of Lenalidomide+Dexamethasone (Rd).

Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 14.9 months, with a 95% CI of (12.1, 17.2).

### Instruction: I’m interested in the median PFS of Lenalidomide+Dexamethasone (Rd). ### Response: Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 14.9 months, with a 95% CI of (12.1, 17.2).

Could you tell me the median PFS for Lenalidomide+Dexamethasone (Rd)?

Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 14.9 months, with a 95% CI of (12.1, 17.2).

### Instruction: Could you tell me the median PFS for Lenalidomide+Dexamethasone (Rd)? ### Response: Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 14.9 months, with a 95% CI of (12.1, 17.2).

What is the median PFS rate for Lenalidomide+Dexamethasone (Rd)?

Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 14.9 months, with a 95% CI of (12.1, 17.2).

### Instruction: What is the median PFS rate for Lenalidomide+Dexamethasone (Rd)? ### Response: Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 14.9 months, with a 95% CI of (12.1, 17.2).

What is the median Progression-Free Survival (PFS) rate in patients treated with Lenalidomide+Dexamethasone (Rd) regimen?

Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 14.9 months, with a 95% CI of (12.1, 17.2).

### Instruction: What is the median Progression-Free Survival (PFS) rate in patients treated with Lenalidomide+Dexamethasone (Rd) regimen? ### Response: Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 14.9 months, with a 95% CI of (12.1, 17.2).

What is the median PFS rate in patients who have undergone Lenalidomide+Dexamethasone (Rd) regimen?

Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 14.9 months, with a 95% CI of (12.1, 17.2).

### Instruction: What is the median PFS rate in patients who have undergone Lenalidomide+Dexamethasone (Rd) regimen? ### Response: Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 14.9 months, with a 95% CI of (12.1, 17.2).

Can you tell me the median Progression-Free Survival rate in patients who were treated with Lenalidomide+Dexamethasone (Rd) regimen?

Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 14.9 months, with a 95% CI of (12.1, 17.2).

### Instruction: Can you tell me the median Progression-Free Survival rate in patients who were treated with Lenalidomide+Dexamethasone (Rd) regimen? ### Response: Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 14.9 months, with a 95% CI of (12.1, 17.2).

What’s the median PFS rate for patients receiving Lenalidomide+Dexamethasone (Rd) regimen?

Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 14.9 months, with a 95% CI of (12.1, 17.2).

### Instruction: What’s the median PFS rate for patients receiving Lenalidomide+Dexamethasone (Rd) regimen? ### Response: Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 14.9 months, with a 95% CI of (12.1, 17.2).

Could you provide the median Progression-Free Survival rate for patients treated with Lenalidomide+Dexamethasone (Rd) regimen?

Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 14.9 months, with a 95% CI of (12.1, 17.2).

### Instruction: Could you provide the median Progression-Free Survival rate for patients treated with Lenalidomide+Dexamethasone (Rd) regimen? ### Response: Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 14.9 months, with a 95% CI of (12.1, 17.2).

What is the median rate of Progression-Free Survival in patients who have been treated with Lenalidomide+Dexamethasone (Rd) regimen?

Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 14.9 months, with a 95% CI of (12.1, 17.2).

### Instruction: What is the median rate of Progression-Free Survival in patients who have been treated with Lenalidomide+Dexamethasone (Rd) regimen? ### Response: Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 14.9 months, with a 95% CI of (12.1, 17.2).

Can you inform me about the median PFS rate in patients that were treated with Lenalidomide+Dexamethasone (Rd) regimen?

Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 14.9 months, with a 95% CI of (12.1, 17.2).

### Instruction: Can you inform me about the median PFS rate in patients that were treated with Lenalidomide+Dexamethasone (Rd) regimen? ### Response: Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 14.9 months, with a 95% CI of (12.1, 17.2).

What is the median PFS rate for patients that have undergone Lenalidomide+Dexamethasone (Rd) regimen?

Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 14.9 months, with a 95% CI of (12.1, 17.2).

### Instruction: What is the median PFS rate for patients that have undergone Lenalidomide+Dexamethasone (Rd) regimen? ### Response: Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 14.9 months, with a 95% CI of (12.1, 17.2).

Could you tell me the median Progression-Free Survival rate for patients who received Lenalidomide+Dexamethasone (Rd) regimen?

Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 14.9 months, with a 95% CI of (12.1, 17.2).

### Instruction: Could you tell me the median Progression-Free Survival rate for patients who received Lenalidomide+Dexamethasone (Rd) regimen? ### Response: Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 14.9 months, with a 95% CI of (12.1, 17.2).

What’s the median rate of PFS in patients treated with Lenalidomide+Dexamethasone (Rd) regimen?

Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 14.9 months, with a 95% CI of (12.1, 17.2).

### Instruction: What’s the median rate of PFS in patients treated with Lenalidomide+Dexamethasone (Rd) regimen? ### Response: Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 14.9 months, with a 95% CI of (12.1, 17.2).

Can you share the median Progression-Free Survival rate in patients who have received Lenalidomide+Dexamethasone (Rd) regimen?

Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 14.9 months, with a 95% CI of (12.1, 17.2).

### Instruction: Can you share the median Progression-Free Survival rate in patients who have received Lenalidomide+Dexamethasone (Rd) regimen? ### Response: Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 14.9 months, with a 95% CI of (12.1, 17.2).

Can you tell me the median PFS for Ixazomib+Lenalidomide+Dexamethasone (IRd)?

Patients treated with the Ixazomib+Lenalidomide+Dexamethasone (IRd) have a median Progression-Free Survival (PFS) rate of 20.6 months, with a 95% CI of None.

### Instruction: Can you tell me the median PFS for Ixazomib+Lenalidomide+Dexamethasone (IRd)? ### Response: Patients treated with the Ixazomib+Lenalidomide+Dexamethasone (IRd) have a median Progression-Free Survival (PFS) rate of 20.6 months, with a 95% CI of None.

What’s the median PFS associated with Ixazomib+Lenalidomide+Dexamethasone (IRd)?

Patients treated with the Ixazomib+Lenalidomide+Dexamethasone (IRd) have a median Progression-Free Survival (PFS) rate of 20.6 months, with a 95% CI of None.

### Instruction: What’s the median PFS associated with Ixazomib+Lenalidomide+Dexamethasone (IRd)? ### Response: Patients treated with the Ixazomib+Lenalidomide+Dexamethasone (IRd) have a median Progression-Free Survival (PFS) rate of 20.6 months, with a 95% CI of None.

Could you provide the median PFS of Ixazomib+Lenalidomide+Dexamethasone (IRd)?

Patients treated with the Ixazomib+Lenalidomide+Dexamethasone (IRd) have a median Progression-Free Survival (PFS) rate of 20.6 months, with a 95% CI of None.

### Instruction: Could you provide the median PFS of Ixazomib+Lenalidomide+Dexamethasone (IRd)? ### Response: Patients treated with the Ixazomib+Lenalidomide+Dexamethasone (IRd) have a median Progression-Free Survival (PFS) rate of 20.6 months, with a 95% CI of None.

I’d like to know the median PFS of Ixazomib+Lenalidomide+Dexamethasone (IRd).

Patients treated with the Ixazomib+Lenalidomide+Dexamethasone (IRd) have a median Progression-Free Survival (PFS) rate of 20.6 months, with a 95% CI of None.

### Instruction: I’d like to know the median PFS of Ixazomib+Lenalidomide+Dexamethasone (IRd). ### Response: Patients treated with the Ixazomib+Lenalidomide+Dexamethasone (IRd) have a median Progression-Free Survival (PFS) rate of 20.6 months, with a 95% CI of None.

Do you have information on the median PFS of Ixazomib+Lenalidomide+Dexamethasone (IRd)?

Patients treated with the Ixazomib+Lenalidomide+Dexamethasone (IRd) have a median Progression-Free Survival (PFS) rate of 20.6 months, with a 95% CI of None.

### Instruction: Do you have information on the median PFS of Ixazomib+Lenalidomide+Dexamethasone (IRd)? ### Response: Patients treated with the Ixazomib+Lenalidomide+Dexamethasone (IRd) have a median Progression-Free Survival (PFS) rate of 20.6 months, with a 95% CI of None.

What is the median progression-free survival (PFS) for Ixazomib+Lenalidomide+Dexamethasone (IRd)?

Patients treated with the Ixazomib+Lenalidomide+Dexamethasone (IRd) have a median Progression-Free Survival (PFS) rate of 20.6 months, with a 95% CI of None.

### Instruction: What is the median progression-free survival (PFS) for Ixazomib+Lenalidomide+Dexamethasone (IRd)? ### Response: Patients treated with the Ixazomib+Lenalidomide+Dexamethasone (IRd) have a median Progression-Free Survival (PFS) rate of 20.6 months, with a 95% CI of None.

Can you inform me about the median PFS for Ixazomib+Lenalidomide+Dexamethasone (IRd)?

Patients treated with the Ixazomib+Lenalidomide+Dexamethasone (IRd) have a median Progression-Free Survival (PFS) rate of 20.6 months, with a 95% CI of None.

### Instruction: Can you inform me about the median PFS for Ixazomib+Lenalidomide+Dexamethasone (IRd)? ### Response: Patients treated with the Ixazomib+Lenalidomide+Dexamethasone (IRd) have a median Progression-Free Survival (PFS) rate of 20.6 months, with a 95% CI of None.

I’m interested in the median PFS of Ixazomib+Lenalidomide+Dexamethasone (IRd).

Patients treated with the Ixazomib+Lenalidomide+Dexamethasone (IRd) have a median Progression-Free Survival (PFS) rate of 20.6 months, with a 95% CI of None.

### Instruction: I’m interested in the median PFS of Ixazomib+Lenalidomide+Dexamethasone (IRd). ### Response: Patients treated with the Ixazomib+Lenalidomide+Dexamethasone (IRd) have a median Progression-Free Survival (PFS) rate of 20.6 months, with a 95% CI of None.

Could you tell me the median PFS for Ixazomib+Lenalidomide+Dexamethasone (IRd)?

Patients treated with the Ixazomib+Lenalidomide+Dexamethasone (IRd) have a median Progression-Free Survival (PFS) rate of 20.6 months, with a 95% CI of None.

### Instruction: Could you tell me the median PFS for Ixazomib+Lenalidomide+Dexamethasone (IRd)? ### Response: Patients treated with the Ixazomib+Lenalidomide+Dexamethasone (IRd) have a median Progression-Free Survival (PFS) rate of 20.6 months, with a 95% CI of None.

What is the median PFS rate for Ixazomib+Lenalidomide+Dexamethasone (IRd)?

Patients treated with the Ixazomib+Lenalidomide+Dexamethasone (IRd) have a median Progression-Free Survival (PFS) rate of 20.6 months, with a 95% CI of None.

### Instruction: What is the median PFS rate for Ixazomib+Lenalidomide+Dexamethasone (IRd)? ### Response: Patients treated with the Ixazomib+Lenalidomide+Dexamethasone (IRd) have a median Progression-Free Survival (PFS) rate of 20.6 months, with a 95% CI of None.

What is the median Progression-Free Survival (PFS) rate in patients treated with Ixazomib+Lenalidomide+Dexamethasone (IRd) regimen?

Patients treated with the Ixazomib+Lenalidomide+Dexamethasone (IRd) have a median Progression-Free Survival (PFS) rate of 20.6 months, with a 95% CI of None.

### Instruction: What is the median Progression-Free Survival (PFS) rate in patients treated with Ixazomib+Lenalidomide+Dexamethasone (IRd) regimen? ### Response: Patients treated with the Ixazomib+Lenalidomide+Dexamethasone (IRd) have a median Progression-Free Survival (PFS) rate of 20.6 months, with a 95% CI of None.

What is the median PFS rate in patients who have undergone Ixazomib+Lenalidomide+Dexamethasone (IRd) regimen?

Patients treated with the Ixazomib+Lenalidomide+Dexamethasone (IRd) have a median Progression-Free Survival (PFS) rate of 20.6 months, with a 95% CI of None.

### Instruction: What is the median PFS rate in patients who have undergone Ixazomib+Lenalidomide+Dexamethasone (IRd) regimen? ### Response: Patients treated with the Ixazomib+Lenalidomide+Dexamethasone (IRd) have a median Progression-Free Survival (PFS) rate of 20.6 months, with a 95% CI of None.

Can you tell me the median Progression-Free Survival rate in patients who were treated with Ixazomib+Lenalidomide+Dexamethasone (IRd) regimen?

Patients treated with the Ixazomib+Lenalidomide+Dexamethasone (IRd) have a median Progression-Free Survival (PFS) rate of 20.6 months, with a 95% CI of None.

### Instruction: Can you tell me the median Progression-Free Survival rate in patients who were treated with Ixazomib+Lenalidomide+Dexamethasone (IRd) regimen? ### Response: Patients treated with the Ixazomib+Lenalidomide+Dexamethasone (IRd) have a median Progression-Free Survival (PFS) rate of 20.6 months, with a 95% CI of None.

What’s the median PFS rate for patients receiving Ixazomib+Lenalidomide+Dexamethasone (IRd) regimen?

Patients treated with the Ixazomib+Lenalidomide+Dexamethasone (IRd) have a median Progression-Free Survival (PFS) rate of 20.6 months, with a 95% CI of None.

### Instruction: What’s the median PFS rate for patients receiving Ixazomib+Lenalidomide+Dexamethasone (IRd) regimen? ### Response: Patients treated with the Ixazomib+Lenalidomide+Dexamethasone (IRd) have a median Progression-Free Survival (PFS) rate of 20.6 months, with a 95% CI of None.

Could you provide the median Progression-Free Survival rate for patients treated with Ixazomib+Lenalidomide+Dexamethasone (IRd) regimen?

Patients treated with the Ixazomib+Lenalidomide+Dexamethasone (IRd) have a median Progression-Free Survival (PFS) rate of 20.6 months, with a 95% CI of None.

### Instruction: Could you provide the median Progression-Free Survival rate for patients treated with Ixazomib+Lenalidomide+Dexamethasone (IRd) regimen? ### Response: Patients treated with the Ixazomib+Lenalidomide+Dexamethasone (IRd) have a median Progression-Free Survival (PFS) rate of 20.6 months, with a 95% CI of None.

What is the median rate of Progression-Free Survival in patients who have been treated with Ixazomib+Lenalidomide+Dexamethasone (IRd) regimen?

Patients treated with the Ixazomib+Lenalidomide+Dexamethasone (IRd) have a median Progression-Free Survival (PFS) rate of 20.6 months, with a 95% CI of None.

### Instruction: What is the median rate of Progression-Free Survival in patients who have been treated with Ixazomib+Lenalidomide+Dexamethasone (IRd) regimen? ### Response: Patients treated with the Ixazomib+Lenalidomide+Dexamethasone (IRd) have a median Progression-Free Survival (PFS) rate of 20.6 months, with a 95% CI of None.

Can you inform me about the median PFS rate in patients that were treated with Ixazomib+Lenalidomide+Dexamethasone (IRd) regimen?

Patients treated with the Ixazomib+Lenalidomide+Dexamethasone (IRd) have a median Progression-Free Survival (PFS) rate of 20.6 months, with a 95% CI of None.

### Instruction: Can you inform me about the median PFS rate in patients that were treated with Ixazomib+Lenalidomide+Dexamethasone (IRd) regimen? ### Response: Patients treated with the Ixazomib+Lenalidomide+Dexamethasone (IRd) have a median Progression-Free Survival (PFS) rate of 20.6 months, with a 95% CI of None.

What is the median PFS rate for patients that have undergone Ixazomib+Lenalidomide+Dexamethasone (IRd) regimen?

Patients treated with the Ixazomib+Lenalidomide+Dexamethasone (IRd) have a median Progression-Free Survival (PFS) rate of 20.6 months, with a 95% CI of None.

### Instruction: What is the median PFS rate for patients that have undergone Ixazomib+Lenalidomide+Dexamethasone (IRd) regimen? ### Response: Patients treated with the Ixazomib+Lenalidomide+Dexamethasone (IRd) have a median Progression-Free Survival (PFS) rate of 20.6 months, with a 95% CI of None.

Could you tell me the median Progression-Free Survival rate for patients who received Ixazomib+Lenalidomide+Dexamethasone (IRd) regimen?

Patients treated with the Ixazomib+Lenalidomide+Dexamethasone (IRd) have a median Progression-Free Survival (PFS) rate of 20.6 months, with a 95% CI of None.

### Instruction: Could you tell me the median Progression-Free Survival rate for patients who received Ixazomib+Lenalidomide+Dexamethasone (IRd) regimen? ### Response: Patients treated with the Ixazomib+Lenalidomide+Dexamethasone (IRd) have a median Progression-Free Survival (PFS) rate of 20.6 months, with a 95% CI of None.

What’s the median rate of PFS in patients treated with Ixazomib+Lenalidomide+Dexamethasone (IRd) regimen?

Patients treated with the Ixazomib+Lenalidomide+Dexamethasone (IRd) have a median Progression-Free Survival (PFS) rate of 20.6 months, with a 95% CI of None.

### Instruction: What’s the median rate of PFS in patients treated with Ixazomib+Lenalidomide+Dexamethasone (IRd) regimen? ### Response: Patients treated with the Ixazomib+Lenalidomide+Dexamethasone (IRd) have a median Progression-Free Survival (PFS) rate of 20.6 months, with a 95% CI of None.

Can you share the median Progression-Free Survival rate in patients who have received Ixazomib+Lenalidomide+Dexamethasone (IRd) regimen?

Patients treated with the Ixazomib+Lenalidomide+Dexamethasone (IRd) have a median Progression-Free Survival (PFS) rate of 20.6 months, with a 95% CI of None.

### Instruction: Can you share the median Progression-Free Survival rate in patients who have received Ixazomib+Lenalidomide+Dexamethasone (IRd) regimen? ### Response: Patients treated with the Ixazomib+Lenalidomide+Dexamethasone (IRd) have a median Progression-Free Survival (PFS) rate of 20.6 months, with a 95% CI of None.

Can you tell me the median PFS for Placebo+Lenalidomide+Dexamethasone (Rd)?

Patients treated with the Placebo+Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 14.7 months, with a 95% CI of None.

### Instruction: Can you tell me the median PFS for Placebo+Lenalidomide+Dexamethasone (Rd)? ### Response: Patients treated with the Placebo+Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 14.7 months, with a 95% CI of None.

What’s the median PFS associated with Placebo+Lenalidomide+Dexamethasone (Rd)?

Patients treated with the Placebo+Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 14.7 months, with a 95% CI of None.

### Instruction: What’s the median PFS associated with Placebo+Lenalidomide+Dexamethasone (Rd)? ### Response: Patients treated with the Placebo+Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 14.7 months, with a 95% CI of None.

Could you provide the median PFS of Placebo+Lenalidomide+Dexamethasone (Rd)?

Patients treated with the Placebo+Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 14.7 months, with a 95% CI of None.

### Instruction: Could you provide the median PFS of Placebo+Lenalidomide+Dexamethasone (Rd)? ### Response: Patients treated with the Placebo+Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 14.7 months, with a 95% CI of None.

I’d like to know the median PFS of Placebo+Lenalidomide+Dexamethasone (Rd).

Patients treated with the Placebo+Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 14.7 months, with a 95% CI of None.

### Instruction: I’d like to know the median PFS of Placebo+Lenalidomide+Dexamethasone (Rd). ### Response: Patients treated with the Placebo+Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 14.7 months, with a 95% CI of None.

Do you have information on the median PFS of Placebo+Lenalidomide+Dexamethasone (Rd)?

Patients treated with the Placebo+Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 14.7 months, with a 95% CI of None.

### Instruction: Do you have information on the median PFS of Placebo+Lenalidomide+Dexamethasone (Rd)? ### Response: Patients treated with the Placebo+Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 14.7 months, with a 95% CI of None.

What is the median progression-free survival (PFS) for Placebo+Lenalidomide+Dexamethasone (Rd)?

Patients treated with the Placebo+Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 14.7 months, with a 95% CI of None.

### Instruction: What is the median progression-free survival (PFS) for Placebo+Lenalidomide+Dexamethasone (Rd)? ### Response: Patients treated with the Placebo+Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 14.7 months, with a 95% CI of None.

Can you inform me about the median PFS for Placebo+Lenalidomide+Dexamethasone (Rd)?

Patients treated with the Placebo+Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 14.7 months, with a 95% CI of None.

### Instruction: Can you inform me about the median PFS for Placebo+Lenalidomide+Dexamethasone (Rd)? ### Response: Patients treated with the Placebo+Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 14.7 months, with a 95% CI of None.

I’m interested in the median PFS of Placebo+Lenalidomide+Dexamethasone (Rd).

Patients treated with the Placebo+Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 14.7 months, with a 95% CI of None.

### Instruction: I’m interested in the median PFS of Placebo+Lenalidomide+Dexamethasone (Rd). ### Response: Patients treated with the Placebo+Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 14.7 months, with a 95% CI of None.

Could you tell me the median PFS for Placebo+Lenalidomide+Dexamethasone (Rd)?

Patients treated with the Placebo+Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 14.7 months, with a 95% CI of None.

### Instruction: Could you tell me the median PFS for Placebo+Lenalidomide+Dexamethasone (Rd)? ### Response: Patients treated with the Placebo+Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 14.7 months, with a 95% CI of None.

What is the median PFS rate for Placebo+Lenalidomide+Dexamethasone (Rd)?

Patients treated with the Placebo+Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 14.7 months, with a 95% CI of None.

### Instruction: What is the median PFS rate for Placebo+Lenalidomide+Dexamethasone (Rd)? ### Response: Patients treated with the Placebo+Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 14.7 months, with a 95% CI of None.

What is the median Progression-Free Survival (PFS) rate in patients treated with Placebo+Lenalidomide+Dexamethasone (Rd) regimen?

Patients treated with the Placebo+Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 14.7 months, with a 95% CI of None.

### Instruction: What is the median Progression-Free Survival (PFS) rate in patients treated with Placebo+Lenalidomide+Dexamethasone (Rd) regimen? ### Response: Patients treated with the Placebo+Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 14.7 months, with a 95% CI of None.

What is the median PFS rate in patients who have undergone Placebo+Lenalidomide+Dexamethasone (Rd) regimen?

Patients treated with the Placebo+Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 14.7 months, with a 95% CI of None.

### Instruction: What is the median PFS rate in patients who have undergone Placebo+Lenalidomide+Dexamethasone (Rd) regimen? ### Response: Patients treated with the Placebo+Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 14.7 months, with a 95% CI of None.

Can you tell me the median Progression-Free Survival rate in patients who were treated with Placebo+Lenalidomide+Dexamethasone (Rd) regimen?

Patients treated with the Placebo+Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 14.7 months, with a 95% CI of None.

### Instruction: Can you tell me the median Progression-Free Survival rate in patients who were treated with Placebo+Lenalidomide+Dexamethasone (Rd) regimen? ### Response: Patients treated with the Placebo+Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 14.7 months, with a 95% CI of None.

What’s the median PFS rate for patients receiving Placebo+Lenalidomide+Dexamethasone (Rd) regimen?

Patients treated with the Placebo+Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 14.7 months, with a 95% CI of None.

### Instruction: What’s the median PFS rate for patients receiving Placebo+Lenalidomide+Dexamethasone (Rd) regimen? ### Response: Patients treated with the Placebo+Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 14.7 months, with a 95% CI of None.

Could you provide the median Progression-Free Survival rate for patients treated with Placebo+Lenalidomide+Dexamethasone (Rd) regimen?

Patients treated with the Placebo+Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 14.7 months, with a 95% CI of None.

### Instruction: Could you provide the median Progression-Free Survival rate for patients treated with Placebo+Lenalidomide+Dexamethasone (Rd) regimen? ### Response: Patients treated with the Placebo+Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 14.7 months, with a 95% CI of None.

What is the median rate of Progression-Free Survival in patients who have been treated with Placebo+Lenalidomide+Dexamethasone (Rd) regimen?

Patients treated with the Placebo+Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 14.7 months, with a 95% CI of None.

### Instruction: What is the median rate of Progression-Free Survival in patients who have been treated with Placebo+Lenalidomide+Dexamethasone (Rd) regimen? ### Response: Patients treated with the Placebo+Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 14.7 months, with a 95% CI of None.

Can you inform me about the median PFS rate in patients that were treated with Placebo+Lenalidomide+Dexamethasone (Rd) regimen?

Patients treated with the Placebo+Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 14.7 months, with a 95% CI of None.

### Instruction: Can you inform me about the median PFS rate in patients that were treated with Placebo+Lenalidomide+Dexamethasone (Rd) regimen? ### Response: Patients treated with the Placebo+Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 14.7 months, with a 95% CI of None.

What is the median PFS rate for patients that have undergone Placebo+Lenalidomide+Dexamethasone (Rd) regimen?

Patients treated with the Placebo+Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 14.7 months, with a 95% CI of None.

### Instruction: What is the median PFS rate for patients that have undergone Placebo+Lenalidomide+Dexamethasone (Rd) regimen? ### Response: Patients treated with the Placebo+Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 14.7 months, with a 95% CI of None.

Could you tell me the median Progression-Free Survival rate for patients who received Placebo+Lenalidomide+Dexamethasone (Rd) regimen?

Patients treated with the Placebo+Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 14.7 months, with a 95% CI of None.

### Instruction: Could you tell me the median Progression-Free Survival rate for patients who received Placebo+Lenalidomide+Dexamethasone (Rd) regimen? ### Response: Patients treated with the Placebo+Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 14.7 months, with a 95% CI of None.

What’s the median rate of PFS in patients treated with Placebo+Lenalidomide+Dexamethasone (Rd) regimen?

Patients treated with the Placebo+Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 14.7 months, with a 95% CI of None.

### Instruction: What’s the median rate of PFS in patients treated with Placebo+Lenalidomide+Dexamethasone (Rd) regimen? ### Response: Patients treated with the Placebo+Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 14.7 months, with a 95% CI of None.

Can you share the median Progression-Free Survival rate in patients who have received Placebo+Lenalidomide+Dexamethasone (Rd) regimen?

Patients treated with the Placebo+Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 14.7 months, with a 95% CI of None.

### Instruction: Can you share the median Progression-Free Survival rate in patients who have received Placebo+Lenalidomide+Dexamethasone (Rd) regimen? ### Response: Patients treated with the Placebo+Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 14.7 months, with a 95% CI of None.

Can you tell me the median PFS for Carfilzomib+Dexamethasone (Kd)?

Patients treated with the Carfilzomib+Dexamethasone (Kd) have a median Progression-Free Survival (PFS) rate of 18.7 months, with a 95% CI of (15.6, NE).

### Instruction: Can you tell me the median PFS for Carfilzomib+Dexamethasone (Kd)? ### Response: Patients treated with the Carfilzomib+Dexamethasone (Kd) have a median Progression-Free Survival (PFS) rate of 18.7 months, with a 95% CI of (15.6, NE).

What’s the median PFS associated with Carfilzomib+Dexamethasone (Kd)?

Patients treated with the Carfilzomib+Dexamethasone (Kd) have a median Progression-Free Survival (PFS) rate of 18.7 months, with a 95% CI of (15.6, NE).

### Instruction: What’s the median PFS associated with Carfilzomib+Dexamethasone (Kd)? ### Response: Patients treated with the Carfilzomib+Dexamethasone (Kd) have a median Progression-Free Survival (PFS) rate of 18.7 months, with a 95% CI of (15.6, NE).

Could you provide the median PFS of Carfilzomib+Dexamethasone (Kd)?

Patients treated with the Carfilzomib+Dexamethasone (Kd) have a median Progression-Free Survival (PFS) rate of 18.7 months, with a 95% CI of (15.6, NE).

### Instruction: Could you provide the median PFS of Carfilzomib+Dexamethasone (Kd)? ### Response: Patients treated with the Carfilzomib+Dexamethasone (Kd) have a median Progression-Free Survival (PFS) rate of 18.7 months, with a 95% CI of (15.6, NE).

I’d like to know the median PFS of Carfilzomib+Dexamethasone (Kd).

Patients treated with the Carfilzomib+Dexamethasone (Kd) have a median Progression-Free Survival (PFS) rate of 18.7 months, with a 95% CI of (15.6, NE).

### Instruction: I’d like to know the median PFS of Carfilzomib+Dexamethasone (Kd). ### Response: Patients treated with the Carfilzomib+Dexamethasone (Kd) have a median Progression-Free Survival (PFS) rate of 18.7 months, with a 95% CI of (15.6, NE).

Do you have information on the median PFS of Carfilzomib+Dexamethasone (Kd)?

Patients treated with the Carfilzomib+Dexamethasone (Kd) have a median Progression-Free Survival (PFS) rate of 18.7 months, with a 95% CI of (15.6, NE).

### Instruction: Do you have information on the median PFS of Carfilzomib+Dexamethasone (Kd)? ### Response: Patients treated with the Carfilzomib+Dexamethasone (Kd) have a median Progression-Free Survival (PFS) rate of 18.7 months, with a 95% CI of (15.6, NE).

What is the median progression-free survival (PFS) for Carfilzomib+Dexamethasone (Kd)?

Patients treated with the Carfilzomib+Dexamethasone (Kd) have a median Progression-Free Survival (PFS) rate of 18.7 months, with a 95% CI of (15.6, NE).

### Instruction: What is the median progression-free survival (PFS) for Carfilzomib+Dexamethasone (Kd)? ### Response: Patients treated with the Carfilzomib+Dexamethasone (Kd) have a median Progression-Free Survival (PFS) rate of 18.7 months, with a 95% CI of (15.6, NE).

Can you inform me about the median PFS for Carfilzomib+Dexamethasone (Kd)?

Patients treated with the Carfilzomib+Dexamethasone (Kd) have a median Progression-Free Survival (PFS) rate of 18.7 months, with a 95% CI of (15.6, NE).

### Instruction: Can you inform me about the median PFS for Carfilzomib+Dexamethasone (Kd)? ### Response: Patients treated with the Carfilzomib+Dexamethasone (Kd) have a median Progression-Free Survival (PFS) rate of 18.7 months, with a 95% CI of (15.6, NE).

I’m interested in the median PFS of Carfilzomib+Dexamethasone (Kd).

Patients treated with the Carfilzomib+Dexamethasone (Kd) have a median Progression-Free Survival (PFS) rate of 18.7 months, with a 95% CI of (15.6, NE).

### Instruction: I’m interested in the median PFS of Carfilzomib+Dexamethasone (Kd). ### Response: Patients treated with the Carfilzomib+Dexamethasone (Kd) have a median Progression-Free Survival (PFS) rate of 18.7 months, with a 95% CI of (15.6, NE).

Could you tell me the median PFS for Carfilzomib+Dexamethasone (Kd)?

Patients treated with the Carfilzomib+Dexamethasone (Kd) have a median Progression-Free Survival (PFS) rate of 18.7 months, with a 95% CI of (15.6, NE).

### Instruction: Could you tell me the median PFS for Carfilzomib+Dexamethasone (Kd)? ### Response: Patients treated with the Carfilzomib+Dexamethasone (Kd) have a median Progression-Free Survival (PFS) rate of 18.7 months, with a 95% CI of (15.6, NE).

What is the median PFS rate for Carfilzomib+Dexamethasone (Kd)?

Patients treated with the Carfilzomib+Dexamethasone (Kd) have a median Progression-Free Survival (PFS) rate of 18.7 months, with a 95% CI of (15.6, NE).

### Instruction: What is the median PFS rate for Carfilzomib+Dexamethasone (Kd)? ### Response: Patients treated with the Carfilzomib+Dexamethasone (Kd) have a median Progression-Free Survival (PFS) rate of 18.7 months, with a 95% CI of (15.6, NE).

What is the median Progression-Free Survival (PFS) rate in patients treated with Carfilzomib+Dexamethasone (Kd) regimen?

Patients treated with the Carfilzomib+Dexamethasone (Kd) have a median Progression-Free Survival (PFS) rate of 18.7 months, with a 95% CI of (15.6, NE).

### Instruction: What is the median Progression-Free Survival (PFS) rate in patients treated with Carfilzomib+Dexamethasone (Kd) regimen? ### Response: Patients treated with the Carfilzomib+Dexamethasone (Kd) have a median Progression-Free Survival (PFS) rate of 18.7 months, with a 95% CI of (15.6, NE).

What is the median PFS rate in patients who have undergone Carfilzomib+Dexamethasone (Kd) regimen?

Patients treated with the Carfilzomib+Dexamethasone (Kd) have a median Progression-Free Survival (PFS) rate of 18.7 months, with a 95% CI of (15.6, NE).

### Instruction: What is the median PFS rate in patients who have undergone Carfilzomib+Dexamethasone (Kd) regimen? ### Response: Patients treated with the Carfilzomib+Dexamethasone (Kd) have a median Progression-Free Survival (PFS) rate of 18.7 months, with a 95% CI of (15.6, NE).

Can you tell me the median Progression-Free Survival rate in patients who were treated with Carfilzomib+Dexamethasone (Kd) regimen?

Patients treated with the Carfilzomib+Dexamethasone (Kd) have a median Progression-Free Survival (PFS) rate of 18.7 months, with a 95% CI of (15.6, NE).

### Instruction: Can you tell me the median Progression-Free Survival rate in patients who were treated with Carfilzomib+Dexamethasone (Kd) regimen? ### Response: Patients treated with the Carfilzomib+Dexamethasone (Kd) have a median Progression-Free Survival (PFS) rate of 18.7 months, with a 95% CI of (15.6, NE).

What’s the median PFS rate for patients receiving Carfilzomib+Dexamethasone (Kd) regimen?

Patients treated with the Carfilzomib+Dexamethasone (Kd) have a median Progression-Free Survival (PFS) rate of 18.7 months, with a 95% CI of (15.6, NE).

### Instruction: What’s the median PFS rate for patients receiving Carfilzomib+Dexamethasone (Kd) regimen? ### Response: Patients treated with the Carfilzomib+Dexamethasone (Kd) have a median Progression-Free Survival (PFS) rate of 18.7 months, with a 95% CI of (15.6, NE).

Could you provide the median Progression-Free Survival rate for patients treated with Carfilzomib+Dexamethasone (Kd) regimen?

Patients treated with the Carfilzomib+Dexamethasone (Kd) have a median Progression-Free Survival (PFS) rate of 18.7 months, with a 95% CI of (15.6, NE).

### Instruction: Could you provide the median Progression-Free Survival rate for patients treated with Carfilzomib+Dexamethasone (Kd) regimen? ### Response: Patients treated with the Carfilzomib+Dexamethasone (Kd) have a median Progression-Free Survival (PFS) rate of 18.7 months, with a 95% CI of (15.6, NE).

What is the median rate of Progression-Free Survival in patients who have been treated with Carfilzomib+Dexamethasone (Kd) regimen?

Patients treated with the Carfilzomib+Dexamethasone (Kd) have a median Progression-Free Survival (PFS) rate of 18.7 months, with a 95% CI of (15.6, NE).

### Instruction: What is the median rate of Progression-Free Survival in patients who have been treated with Carfilzomib+Dexamethasone (Kd) regimen? ### Response: Patients treated with the Carfilzomib+Dexamethasone (Kd) have a median Progression-Free Survival (PFS) rate of 18.7 months, with a 95% CI of (15.6, NE).

Can you inform me about the median PFS rate in patients that were treated with Carfilzomib+Dexamethasone (Kd) regimen?

Patients treated with the Carfilzomib+Dexamethasone (Kd) have a median Progression-Free Survival (PFS) rate of 18.7 months, with a 95% CI of (15.6, NE).

### Instruction: Can you inform me about the median PFS rate in patients that were treated with Carfilzomib+Dexamethasone (Kd) regimen? ### Response: Patients treated with the Carfilzomib+Dexamethasone (Kd) have a median Progression-Free Survival (PFS) rate of 18.7 months, with a 95% CI of (15.6, NE).

What is the median PFS rate for patients that have undergone Carfilzomib+Dexamethasone (Kd) regimen?

Patients treated with the Carfilzomib+Dexamethasone (Kd) have a median Progression-Free Survival (PFS) rate of 18.7 months, with a 95% CI of (15.6, NE).

### Instruction: What is the median PFS rate for patients that have undergone Carfilzomib+Dexamethasone (Kd) regimen? ### Response: Patients treated with the Carfilzomib+Dexamethasone (Kd) have a median Progression-Free Survival (PFS) rate of 18.7 months, with a 95% CI of (15.6, NE).

Could you tell me the median Progression-Free Survival rate for patients who received Carfilzomib+Dexamethasone (Kd) regimen?

Patients treated with the Carfilzomib+Dexamethasone (Kd) have a median Progression-Free Survival (PFS) rate of 18.7 months, with a 95% CI of (15.6, NE).

### Instruction: Could you tell me the median Progression-Free Survival rate for patients who received Carfilzomib+Dexamethasone (Kd) regimen? ### Response: Patients treated with the Carfilzomib+Dexamethasone (Kd) have a median Progression-Free Survival (PFS) rate of 18.7 months, with a 95% CI of (15.6, NE).

What’s the median rate of PFS in patients treated with Carfilzomib+Dexamethasone (Kd) regimen?

Patients treated with the Carfilzomib+Dexamethasone (Kd) have a median Progression-Free Survival (PFS) rate of 18.7 months, with a 95% CI of (15.6, NE).

### Instruction: What’s the median rate of PFS in patients treated with Carfilzomib+Dexamethasone (Kd) regimen? ### Response: Patients treated with the Carfilzomib+Dexamethasone (Kd) have a median Progression-Free Survival (PFS) rate of 18.7 months, with a 95% CI of (15.6, NE).

Can you share the median Progression-Free Survival rate in patients who have received Carfilzomib+Dexamethasone (Kd) regimen?

Patients treated with the Carfilzomib+Dexamethasone (Kd) have a median Progression-Free Survival (PFS) rate of 18.7 months, with a 95% CI of (15.6, NE).

### Instruction: Can you share the median Progression-Free Survival rate in patients who have received Carfilzomib+Dexamethasone (Kd) regimen? ### Response: Patients treated with the Carfilzomib+Dexamethasone (Kd) have a median Progression-Free Survival (PFS) rate of 18.7 months, with a 95% CI of (15.6, NE).

Can you tell me the median PFS for Bortezomib+Dexamethasone (Vd)?

Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 9.4 months, with a 95% CI of (8.4, 10.4).

### Instruction: Can you tell me the median PFS for Bortezomib+Dexamethasone (Vd)? ### Response: Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 9.4 months, with a 95% CI of (8.4, 10.4).

What’s the median PFS associated with Bortezomib+Dexamethasone (Vd)?

Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 9.4 months, with a 95% CI of (8.4, 10.4).

### Instruction: What’s the median PFS associated with Bortezomib+Dexamethasone (Vd)? ### Response: Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 9.4 months, with a 95% CI of (8.4, 10.4).

Could you provide the median PFS of Bortezomib+Dexamethasone (Vd)?

Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 9.4 months, with a 95% CI of (8.4, 10.4).

### Instruction: Could you provide the median PFS of Bortezomib+Dexamethasone (Vd)? ### Response: Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 9.4 months, with a 95% CI of (8.4, 10.4).

I’d like to know the median PFS of Bortezomib+Dexamethasone (Vd).

Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 9.4 months, with a 95% CI of (8.4, 10.4).

### Instruction: I’d like to know the median PFS of Bortezomib+Dexamethasone (Vd). ### Response: Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 9.4 months, with a 95% CI of (8.4, 10.4).

Do you have information on the median PFS of Bortezomib+Dexamethasone (Vd)?

Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 9.4 months, with a 95% CI of (8.4, 10.4).

### Instruction: Do you have information on the median PFS of Bortezomib+Dexamethasone (Vd)? ### Response: Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 9.4 months, with a 95% CI of (8.4, 10.4).

What is the median progression-free survival (PFS) for Bortezomib+Dexamethasone (Vd)?

Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 9.4 months, with a 95% CI of (8.4, 10.4).

### Instruction: What is the median progression-free survival (PFS) for Bortezomib+Dexamethasone (Vd)? ### Response: Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 9.4 months, with a 95% CI of (8.4, 10.4).

Can you inform me about the median PFS for Bortezomib+Dexamethasone (Vd)?

Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 9.4 months, with a 95% CI of (8.4, 10.4).

### Instruction: Can you inform me about the median PFS for Bortezomib+Dexamethasone (Vd)? ### Response: Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 9.4 months, with a 95% CI of (8.4, 10.4).

I’m interested in the median PFS of Bortezomib+Dexamethasone (Vd).

Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 9.4 months, with a 95% CI of (8.4, 10.4).

### Instruction: I’m interested in the median PFS of Bortezomib+Dexamethasone (Vd). ### Response: Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 9.4 months, with a 95% CI of (8.4, 10.4).

Could you tell me the median PFS for Bortezomib+Dexamethasone (Vd)?

Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 9.4 months, with a 95% CI of (8.4, 10.4).

### Instruction: Could you tell me the median PFS for Bortezomib+Dexamethasone (Vd)? ### Response: Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 9.4 months, with a 95% CI of (8.4, 10.4).

What is the median PFS rate for Bortezomib+Dexamethasone (Vd)?

Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 9.4 months, with a 95% CI of (8.4, 10.4).

### Instruction: What is the median PFS rate for Bortezomib+Dexamethasone (Vd)? ### Response: Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 9.4 months, with a 95% CI of (8.4, 10.4).

What is the median Progression-Free Survival (PFS) rate in patients treated with Bortezomib+Dexamethasone (Vd) regimen?

Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 9.4 months, with a 95% CI of (8.4, 10.4).

### Instruction: What is the median Progression-Free Survival (PFS) rate in patients treated with Bortezomib+Dexamethasone (Vd) regimen? ### Response: Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 9.4 months, with a 95% CI of (8.4, 10.4).